Kwality Pharmaceuticals Ltd (KPL)
·Next Day Close·+1.31%·₹3,627.05
Key EventTrading window closure announced ahead of financial results
Kwality Pharmaceuticals Ltd (KPL)
·Next Day Close·-1.42%·₹3,342.95
Key EventAll resolutions passed at 43rd AGM with requisite majority
ImpactShareholders approved all key governance and financial items, confirming board continuity and auditor remuneration.Sign up to read impact
Kwality Pharmaceuticals Ltd (KPL)
·Next Day Close·-1.42%·₹3,342.95
Key EventKwality Pharmaceuticals reappoints Swanith Kapoor as Independent Director and Aditya Arora as Whole Time Director.
ImpactThese appointments ensure continuity in governance and operational leadership, supporting long-term stability.Sign up to read impact
Kwality Pharmaceuticals Ltd (KPL)
·Next Day Close·+3.1%·₹3,387.5
Key EventKwality Pharmaceuticals conducted its 43rd AGM on August 31, 2026 via video conference with 34 shareholders present.
ImpactShareholders approved key governance and financial items, including financial statements and director reappointments.Sign up to read impact
Kwality Pharmaceuticals Ltd (KPL)
·Next Day Close·-3.48%·₹2,704.7
Key EventKwality Pharmaceuticals reported Q1 FY27 results with oncology revenue at 20% of total, down from 26%, and reaffirmed FY27 revenue guidance of INR700+ crores with 26-27% EBITDA margins.
ImpactThe company is shifting focus to oncology growth and global expansion while targeting higher margins and revenue by FY30.Sign up to read impact
Kwality Pharmaceuticals Ltd (KPL)
·Next Day Close·+7.48%·₹1,404.1
Key EventKwality Pharmaceuticals reported FY26 revenue of INR503 crores (up 36% YoY) and PAT of INR67 crores (up 69%), with margins expanding to 13.4% from 10.8% due to operational efficiencies.
ImpactKwality Pharmaceuticals is accelerating growth in high-margin oncology and regulated markets, with clear FY27-FY29 targets and capex plans to scale revenue to INR1,000 crores by FY29 while maintaining margin expansion and stable working capital.Sign up to read impact